BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the size of their tumors. CNS Pharmaceuticals is advancing the development of Berubicin for potential commercialization in treating glioblastoma multiforme (“GBM”), a type of brain cancer that is nearly 100% fatal in one year after diagnosis. The company has progressed its plans for a world-spanning Phase 2 trial comparing Berubicin’s response to the effectiveness of established chemotherapy drug lomustine in 243 GBM patients. “The participants for the Phase 2 study will be adult GBM patients with recurrent disease (Grade IV, as measured by the World Health Organization) after the failure of standard first-line therapy,” reads a recent article on the new trial. “The primary endpoint of the study is to demonstrate overall survival, ‘a rigorous endpoint the FDA recognizes when a statistically significant improvement can be shown relative to a randomized control arm,’ the company states.”

To view the full article, visit https://ibn.fm/AEyIb

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork